The government of Canada announced the start of the trials of a new vaccine against Ebola virus in humans. The vaccine was named VSV-EBOV. A series of animal testing was successful, and now the time for clinical research.
The authorship of the drug belongs NewLink Genetics corporation. The company specializes in the production of anti-cancer drugs.
Now VSV-EBOV experience for the volunteers at the clinic Halifax. In parallel with these studies are testing vaccines in the Research Institute of the U.S. army Walter reed (Maryland).
The first data on the efficacy and safety of the vaccine will be published in 2015.